Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 VaccinationJAMA Neurol 2022 Jan 24;[EPub Ahead of Print], M König, HM Torgauten, TT Tran, T Holmøy, JT Vaage, F Lund-Johansen, GO Nygaard
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.